Please set your featured image
Prosensa achieve title as ‘Fierce 15 Biotech Company’
This September, Prosensa announced that their company, that focuses on RNA-modulating therapeutics for rare diseases with high unmet demand, has been named by FierceBiotech as one of the faces of 2012’s Fierce 15, classifying Prosensa as one of the most promising private biotechnology companies in the industry.
Prosensa’s primary research focus is on the treatment of rare neuromuscular diseases including their leading cure for the treatment of Duchenne Muscular Dystrophy (DMD), which is currently in Phase III trials and partners with GlaxoSmithKline.
Prosensa set up a base in the UK two years ago where they located on site at Begbroke Science Park. The company have taken full advantage of the wide-spread associations to the community at Oxford University and the unlimited links to industry.
The CEO of Prosensa, Hans Schikan is grateful to ‘be recognised’ and this achievement will continue to drive Prosensa. The team will ‘passionately continue on our path of growth to become a leading rare disease player.’ Prosensa’s platform of RNA modulation is limitless and can be applied to a number of unmet medical needs.